Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine mesylate for cognitive function in peripheral vestibular dysfunction
jRCT1031210699Recruiting
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of betahistine in Peripheral vertigo, Mild Cognitive Impairment (MCI) and Dementia (2 arms). Primary endpoint: Change in Benton Visual Retention Test score at 12 weeks. Started Mar 2022; status: recruiting.
02
Drugs
betahistine
03
Conditions
Peripheral vertigoMild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on jRCT1031210699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210699.